The Swiss drugmaker intends to launch a tender offer for the 44.2% of Genentech it doesn’t already own at $86.50 a share, a lower price than the $89 a share offer it made in July. More: continued here
The Swiss drugmaker intends to launch a tender offer for the 44.2% of Genentech it doesn’t already own at $86.50 a share, a lower price than the $89 a share offer it made in July. More: continued here
Eric Bolling advises how to invest in the infrastructure space. More: continued here
Stocks in Asia closed mixed on news that showed Japanese industrial production falling at a record pace and profits tumbling at some leading corporations. More: continued here
Bad loans and steep equity losses forced the Japanese bank to slash its full-year net profit outlook by 60%. More: continued here
Japan’s No. 2 automaker saw net profit tumble 90% in the October-December quarter, and it cut its net profit forecast for the fiscal year. More: continued here
The Japanese electronics maker predicted it would post a massive net loss this fiscal year and said it will slash about 7,000 jobs as part of a global restructuring. More: continued here
Fannie Mae has reached an agreement to work with one of its former critics to prevent further foreclosures by reworking home mortgages, a report says. More: continued here
Morgan Stanley and Goldman Sachs are contemplating further job cuts after slashing staff in 2008. More: continued here
CHICAGO—-Four free stock picks are being made available today on Zacks.com. The industry?s leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value. More: continued here